HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 08, August 2017 – Eye – the Window to your Soul       » Palm-Sized PCR Device for Rapid Real-Time Detection of Viruses       » Scientists Uncover New Mechanism for Diabetic Neuropathy       » China Enlists AI to Diagnose Breast Cancer       » Philips and Singapore Institute of Advanced Medicine Holdings Sign Agreement to Open First-of-its-kind Oncology Center in Singapore       » Guardian Partners with MyDoc to Address Singapore's Population Health Needs through Integrating Technology and Self-Care       » Database Boosts Shanghai's Technology Aim      
INSIDE INDUSTRY
Knopp Biosciences and NIH to collaborate in evaluating dexpramipexole in patients with hypereosinophilic syndrome
Knopp Biosciences LLC has entered a collaboration agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a clinical trial of dexpramipexole in hypereosinophilic syndrome (HES).

Under the Cooperative Research and Development Agreement (CRADA), NIAID will sponsor the Phase 2 proof-of-concept trial, while Knopp will provide the dexpramipexole study drug and will collaborate on trial design and study oversight.

The 24-week, open-label clinical trial in HES subjects receiving corticosteroid therapy is expected to initiate enrollment in the first quarter of this year at the NIH Clinical Center in Bethesda, MD. The principal investigator is Amy Klion, M.D., immediate past president of the International Eosinophil Society and chief of the Eosinophil Pathology Unit of NIAID's Laboratory of Parasitic Diseases.

The principal objective of the trial is to evaluate the potential of dexpramipexole to reduce long-term and acute treatment with corticosteroids in people with HES while maintaining or reducing eosinophil count. Data presented at the July 2013 meeting of the International Eosinophilia Society in Oxford, England, demonstrated that dexpramipexole safely and persistently reduced blood eosinophil counts by approximately 70% (p < 0.0001) in people with amyotrophic lateral sclerosis (ALS) enrolled in a large Phase 3 trial (n=943).

Evidence from multiple preclinical and ALS clinical studies showing that dexpramipexole reduces blood eosinophils is the basis for the hypothesis that the drug may be a potential treatment for HES, for which off-label corticosteroid administration remains first-line treatment. HES is a collection of rare disorders characterized by excess levels of circulating eosinophils, a type of white blood cell, eventually leading to tissue damage in end organs. Dr. Klion will evaluate the primary endpoint of minimally effective corticosteroid dose reduction after treatment with dexpramipexole.

"Knopp is very pleased to collaborate with a researcher of Dr. Klion's experience and leadership in evaluating investigational treatments for HES," said Michael Bozik, M.D., president and CEO of Knopp. "HES is a very serious orphan disease with limited treatment options, and we expect this collaboration to provide an important assessment of the drug's potential for benefiting patients with this aggressive immunological disease."

In addition to assessing the potential of dexpramipexole as a corticosteroid-sparing treatment for HES, the planned Phase 2 study will examine drug effects on bone marrow eosinophils and myeloid precursors prior to steroid taper; changes in tissue eosinophils; and measures of eosinophil activation, cytokine/chemokine profile, and other immunologic parameters.

Study objectives also include evaluating the safety of 150 mg of dexpramipexole administered twice daily in HES patients currently treated with corticosteroids. The selection of dose and regimen is based on the safety and tolerability of dexpramipexole in earlier clinical studies of healthy volunteers and ALS subjects receiving 50 mg, 150 mg, and 300 mg total daily doses and in a healthy volunteer study of 600 mg total daily dose.

Source: Business Wire

Click here for the complete issue.

NEWS CRUNCH  
news Vitafoods Asia 2017: Industry players optimistic of future
news Nestlé Introduces their Singapore R&D Centre
news Vitafoods Asia Elevates 2017 Learning Programme
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy